ReneuBio develops small‑molecule therapeutics that restore the regenerative capacity of the aging brain by reactivating dormant neural stem cells. Using its Innovation Engine, the company directly screens aged cells and brain tissue to identify age‑specific targets, with a lead program validated in a Nature‑published study for conditions such as chemobrain, stroke, and Alzheimer’s disease.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related brain disorders such as chemotherapy‑induced cognitive impairment, stroke, and Alzheimer’s disease are increasing as the global population ages, yet the aging brain loses its intrinsic capacity for regeneration and repair.
Solution
ReneuBio is developing small‑molecule therapeutics that restore the regenerative potential of the aged brain by reactivating dormant neural stem cells. The company’s Innovation Engine directly screens aged cells and brain tissue, enabling the discovery of targets that are uniquely relevant to the aging environment. A Nature‑published proof‑of‑concept study validates this approach and has identified a genetically validated pathway that enhances neural regeneration. Lead candidates are designed to modulate this pathway, aiming to promote resilience, tissue repair, and functional recovery in age‑related neurological conditions. By focusing on mechanisms that revive the brain’s own healing processes, ReneuBio seeks to provide disease‑modifying treatments for a range of age‑associated brain disorders.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic and clinical research groups developing therapies for age‑related neurodegenerative and cerebrovascular disorders.
Features
- Innovation Engine that screens old cells and whole aged brain tissue to uncover age‑specific therapeutic targets
- Small‑molecule platform designed to reactivate dormant neural stem cells and stimulate endogenous regeneration
- Genetically validated pathway target demonstrated to enhance brain repair in aged models
- Proof‑of‑concept results published in Nature (2024), confirming target relevance and translational potential
- Pipeline focused on age‑related neurological diseases including chemobrain, stroke, and Alzheimer’s disease